Edwards Lifesciences (NYSE:EW) Stock Price Target Raised at BTIG Research

Edwards Lifesciences (NYSE:EW) had its price target upped by investment analysts at BTIG Research from $110.00 to $115.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. BTIG Research‘s price objective indicates a potential upside of 15.71% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the company. Mizuho set a $120.00 price target on Edwards Lifesciences in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, October 2nd. Robert W. Baird upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating and set a $116.00 price target on the stock in a research note on Thursday. Deutsche Bank Aktiengesellschaft set a $104.00 target price on Edwards Lifesciences in a research note on Tuesday, October 27th. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.08.

Edwards Lifesciences Stock Up 4.4%

EW opened at $99.39 on Thursday. Edwards Lifesciences has a one year low of $74.66 and a one year high of $100.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a market capitalization of $57.23 billion, a P/E ratio of 57.12, a price-to-earnings-growth ratio of 2.49 and a beta of 0.85. The company has a fifty day moving average price of $88.48 and a 200-day moving average price of $85.61.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 10.5% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total value of $53,017.35. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,428,912.10. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 5,045 shares of company stock worth $451,596. Insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in Edwards Lifesciences in the 2nd quarter valued at approximately $1,274,082,000. Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $605,397,000. Deutsche Bank AG acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Edwards Lifesciences by 0.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after acquiring an additional 30,495 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, topping the $0.74 consensus, and revenue of $1.72 billion versus expectations of $1.68 billion. Revenue grew year over year, while the company raised its full-year outlook and narrowed its 2026 forecast range. Q3 earnings, revenue and outlook
• Positive Sentiment: Truist Financial upgraded EW from “hold” to “strong-buy,” adding analyst support. Truist upgrade
• Positive Sentiment: Management highlighted strong momentum in its transcatheter mitral and tricuspid therapies business, with TMTT sales up 44%. Separately, trial results for the PASCAL tricuspid repair system showed better outcomes than medical therapy through one year, supporting the product’s potential. Q3 results and TMTT growth PASCAL trial results
• Negative Sentiment: CEO commentary acknowledged that more TAVR competition is coming, which could pressure Edwards’ position in a key market. RBC also said the Progress trial data is unlikely to meaningfully expand the transcatheter market, limiting the potential upside from that study. TAVR competition RBC assessment of Progress trial

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.